Specific Diagnostics Revenue and Competitors
Estimated Revenue & Valuation
- Specific Diagnostics's estimated annual revenue is currently $6.3M per year.
- Specific Diagnostics's estimated revenue per employee is $125,500
- Specific Diagnostics's total funding is $15.9M.
Employee Data
- Specific Diagnostics has 50 Employees.
- Specific Diagnostics grew their employee count by -18% last year.
Specific Diagnostics's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Sales, US (Sold to bióMerieux in May, 2022 for $425M) | Reveal Email/Phone |
2 | VP Sales, US | Reveal Email/Phone |
3 | R&D Operations Director | Reveal Email/Phone |
4 | Project Manager | Reveal Email/Phone |
5 | Quality Assurance Engineer at Specific Diagnostics | Reveal Email/Phone |
6 | Strategic Account Director | Reveal Email/Phone |
7 | Associate Principal Equipment Engineer | Reveal Email/Phone |
8 | Finance, Operations, and Development | Reveal Email/Phone |
9 | R&D Microbiologist | Reveal Email/Phone |
10 | R&D Microbiologist | Reveal Email/Phone |
Specific Diagnostics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Specific Diagnostics?
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specificᅢᄁ¬ツᆲ¬トᄁs Revealᅢᄁ¬ダᅡᄁ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specificᅢᄁ¬ツᆲ¬トᄁs unique patented technology leverages a low-cost small molecule sensor (SMS) array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specificᅢᄁ¬ツᆲ¬トᄁs system streamlines lab workflow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast-moving and deadly drug-resistant blood infections. Specific and its founders have written almost 60 peer-reviewed publications, detailing the successful demonstration of the SMS array technology. The Company itself has independently authored over 20 scientific publications and conference abstracts detailing the SMS array powered detection, identification and antibiotic susceptibility testing. Specific is located in Mountain View, California. For more information, visit www.specificdx.com. Corporate Contact, email: press@specificdx.com
keywords:Medical Devices, Diagnostics, Heathcare$15.9M
Total Funding
50
Number of Employees
$6.3M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Specific Diagnostics News
Developments in molecular diagnostics have been vital in discovering ... FokI is a unique restriction enzyme that identifies a certain DNA...
Specific Diagnostics has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid...
Metabolite perturbations are evaluated based on current knowledge of specific metabolic pathway deficiencies, a manual diagnostic process that...
“Every lab we encounter wants rapid, easy-to-use susceptibility testing at the right price; we couldn’t reach them all without partnering with an organization with the scale and quality of bioMérieux,” said Paul A. Rhodes, Ph.D., CEO of Specific. SAN JOSE, Calif. (PRWEB) June 29, 2021 In the c ...
MOUNTAIN VIEW, California, June 2, 2020 – Specific Diagnostics today announces that the National Institute for Allergy and Infectious Disease (NIAID) has awarded a second major grant to drive the commercial introduction of Specific’s Reveal system, which provides quantitative determination of an ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.8M | 50 | 11% | N/A |
#2 | $10.8M | 50 | 4% | N/A |
#3 | $8.1M | 50 | 2% | N/A |
#4 | $11M | 50 | 43% | N/A |
#5 | $10.5M | 50 | -9% | $67.4M |